Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma.
Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague 10, Czech Republic.
M
M
Arenbergerova
Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague 10, Czech Republic.
A
A
Fialova
Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague 10, Czech Republic.
S
S
Gkalpakiotis
Department of Pathology and Molecular Medicine, 2nd Faculty of Medicine, Charles University, Prague 5, Czech Republic.
R
R
Kodet
Department of Hematology, Third Faculty of Medicine, Charles University, Prague 10, Czech Republic.
T
T
Jancarkova
Department of Radiodiagnostics, Liberec Hospital, Liberec, Czech Republic.
M
M
Novotna
Division of Hematology - Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
A
A
Hess
Division of Hematology - Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
I
I
Puzanov
Department of Dermatovenereology, Third Faculty of Medicine, Charles University, Prague 10, Czech Republic.
P
P
Arenberger
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000074324:Ipilimumab; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis*; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab